Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...

Valued at a market cap of $143.8 billion, Gilead Sciences, Inc. (GILD ... becomes more evident when compared to its rival, Amgen Inc. (AMGN), which gained 14.4% over the past 52 weeks and 21.5 ...

Raffat covers the Healthcare sector, focusing on stocks such as Amgen, Eli Lilly & Co, and Biogen. Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $105. ...

BofA raised the firm’s price target on Gilead (GILD) to $126 from $116 and keeps a Buy rating on the shares. For the last several weeks, ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Amgen profits rise, next MariTide studies ... Gilead 3rd-quarter results beat Wall Street estimates, raises outlook Gilead Sciences reported third-quarter financial results that handily beat ...

Gilead Sciences beat analysts’ revenue expectations ... beating analysts’ expectations by 1.9%, and Amgen reported revenues up 10.9%, topping estimates by 2.6%. AbbVie traded up 8.3% following ...